FY25 HEPLISAV-B net product revenue is expected in the range of $305M to $325M Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks recommended by analysts >> Read More on DVAX: DVAX Earnings this Week: How Will it Perform? Dynavax Appoints New Principal Accounting Officer Buy/Sell: Wall Street’s top 10 stock calls this week IBM initiated, Southwest upgraded: Wall Street’s top analyst calls Dynavax downgraded to Sell from Neutral at Goldman Sachs Disclaimer & DisclosureReport an Issue
